Evidence map›Paper›PMID 33980132›Full record

ArticleVirulence2021

Deletion of N-acetylmuramyl-L-alanine amidases alters the host immune response to

Nathan Scott Kieswetter, Mumin Ozturk, Shelby-Sara Jones, Sibusiso Senzani, Melissa Dalcina Chengalroyen, Frank Brombacher, Bavesh Kana, Reto Guler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. The progress ofFrontiers in medicine · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Nathan Scott KieswetterCape Town Component, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.
Mumin OzturkCape Town Component, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.
Shelby-Sara JonesCape Town Component, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.
Sibusiso SenzaniDST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, National Health Laboratory Service, University of the Witwatersrand, Johannesburg, South Africa.
Melissa Dalcina ChengalroyenDST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, National Health Laboratory Service, University of the Witwatersrand, Johannesburg, South Africa.
Frank BrombacherCape Town Component, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.
Bavesh KanaDST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, National Health Laboratory Service, University of the Witwatersrand, Johannesburg, South Africa.
Reto GulerCape Town Component, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.
University of Cape Town · ZAUniversity of the Witwatersrand · ZAInternational Centre for Genetic Engineering and Biotechnology · ZAWellcome Centre for Infectious Diseases Research in Africa · ZA

Funding

Wellcome Trust
6 · The paper itself

Abstract

Peptidoglycan (PG), a heteropolysaccharide component of the mycobacterial cell wall can be shed during tuberculosis infection with immunomodulatory consequences. As such, changes in PG structure are expected to have important implications on disease progression and host responses during infection with

Indexed as

Mycobacterium tuberculosisTuberculosisAlanineAmidohydrolasesAnimalsCytokinesImmunityMiceMice, Inbred C57BLPeptidoglycanAlanineAmidohydrolasesCytokinesPeptidoglycanAmi1Ami4amidasehost–pathogen interactionimmunopathologymacrophagemicemutantMycobacterium tuberculosis

Identifiers

PMID33980132
PMCPMC8128173
OpenAlexW3162436116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.